Funding opportunity
The UK Technology Strategy Board (TSB) is to invest a further £6 million in regenerative medicine research and development and is inviting UK companies to bid for funding through two new competitions.
As part of a £21.5m programme in regenerative medicine, the TSB will invest up to £4 million in commercial research and development projects in regenerative medicine therapeutics in one competition, while in the second up to £2 million is available for feasibility projects in regenerative medicine tools and technologies. Both competitions open on 8 March 2010.
The aim of the first competition is to enable UK companies to carry out preclinical and clinical development of regenerative medicine therapeutic products and accelerate product development.
The Tools and Technologies Feasibility Studies competition is to solve problems currently being faced by developers of regenerative medicine therapeutics through the development of platform technologies. Particular issues include assessing the safety and/or efficacy of cell therapy products and being able to develop reproducible and robust manufacturing processes.
The TSB launched a £21.5 million programme in regenerative medicine in September 2009. In January it announced its first investments through the programme, with 30 feasibility studies receiving £2.8 million of funding while two major collaborative research and development projects received a further £1.7 million.
For more information, visit: http://www.innovateuk.org/content/competition-announcements/media-alert-6-million-to-be-invested-in-further-re.ashx
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
